跳至主要内容
临床试验/JPRN-UMIN000012267
JPRN-UMIN000012267已完成未知

Prospective, randomized, open-label, clinical trial comparing the effects of bezafibrate and ethyl icosapentate/docosahexaenoate combination on progression of atherosclerotic plaques, endothelial function and markers for inflammation - Prospective, randomized, open-label, clinical trial comparing the effects of bezafibrate and ethyl icosapentate/docosahexaenoate combination

ational Defense Medical College0 个研究点目标入组 66 人开始时间: 2013年11月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Allergy against bezafibrate or ethyl icosapentate/docosahexaenoate 2) Poor controlled diabetes mellitus (HbA1c>10%) 3) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 4) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 5) eGFR 30 mL/min/1.73 m2 or less (in case of the subjects treated statins, eGFR 60 mL/min/1.73 m2 or less) 6) Symptomatic (NYHA III or IV) congestive heart failure 7) Malignancies or other diseases with poor prognosis 8) Pregnant 9) Severe infection/trauma 10) Subjects who statins treatment is recommended by Guideline of Japan Atherosclerotic Society 2012. 11) Subjects whose doctor in charge do not agree to join the trial

研究者

发起方
ational Defense Medical College

相似试验